Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC1001 Bis-5-methyl-cyclosal-d4tmp
Novel anti-HIV active dimeric prodrug of 2‘,3‘-dideoxy-2‘,3‘-didehydrothymidine monophosphate (d4TMP)
More description
DCC1000 Bis-2-ai Adjuvant-2
Novel adjuvant to repurpose azithromycin for use against Pseudomonas aeruginosa, exhibiting a 1024-fold reduction in the minimum inhibitory concentration of azithromycin in vitro and displays activity in a Galleria mellonella model of infection
More description
DCC0999 Biphalin
Potent peptide opioid receptor agonist, alleviating LPS-Induced activation in rat primary microglial cultures in opioid receptor-dependent and receptor-independent manners
More description
DCC0998 Biph(2,3',4,5',6)p5
Potent inhibitor of SHIP-2 catalytic activity; Novel inositol polyphosphate surrogate modulating Ca responses in rat hepatocytes
More description
DCC0997 Bipbipu
Novel heparanase inhibitor
More description
DCC0996 Bio-0554019
Novel selective RORgamma inhibitor, selectively inhibiting Th17 differentiation and RORgamma signature gene expression
More description
DCC0995 Bin-01-07-07
Novel USP28 inhibitor
More description
DCC0994 bim5078
Potent HNF4α antagonist
More description
DCC0993 Biliatresone
Natural Biliary Toxin, causing extrahepatic biliary atresia
More description
DCC0992 Biii-890cl
Novel potent blocker of Nav1.2 sodium channels, protecting of brain tissue from ischemia
More description
DCC0991 Biii-277cl
Novel potent blocker of the NMDA receptor ion channel
More description
DCC0990 Biib068 Hemi-adipate
Novel, Selective, Potent, Reversible Bruton's Tyrosine Kinase (BTK) Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases
More description
DCC0989 Biib-057
Selective Syk inhibitor
More description
DCC0988 Biib028
Novel selective heat shock protein 90 inhibitor, prodrug of CF2772
More description
DCC0987 Bifeprunox Mesylate
Partial agonist at dopamine D2 and serotonin 1A receptors
More description
DCC0986 Biemamide A
Novel inhibitor of the TGF-β pathway, blocking the epithelial to mesenchymal transition
More description
DCC0985 bicuculline Methobromide
GABAA receptor antagonist
More description
DCC0984 Biclofibrate
Antilipidemic agent
More description
DCC0983 Bicifadine
Triple reuptake inhibitor (TRI)
More description
DCC0982 Bibx-1382 Dihydrochloride
Potent, selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase
More description
DCC0981 Bi-btk-1
Novel, highly selective and potent irreversible BTK inhibitor
More description
DCC0980 Bibs-222
Novel nonpeptide angiotensin II receptor antagonist
More description
DCC0979 Bi-9740
Novel potent, highly selective, and orally bioavailable CATHEPSIN C (CTSC, CatC) inhibitor
More description
DCC0978 bi-83c11
Non-ATP competitive inhibitor of JNK, targeting the JNK-JIP interaction
More description
DCC0977 Bi-730357
Novel RORγ antagonist for the treatment of autoimmune diseases
More description
DCC0976 Bi-7273
Novel highly potent dual inhibitor of BRD9/BRD7
More description
DCC0975 Bi-5521
Novel potent and selective ATP-competitive inhibitor of glycogen synthase kinase (GSK-3), targeting both isoforms GSK-3α and GSK-3β
More description
DCC0974 Bi-4659
Novel potent and selective inhibitor of Alk5 (TGFßR1), blocking the phosphorylation of Smad2 and Smad3 in HaCaT cells
More description
DCC0973 Bi-3257
Novel inhibitor of HIV replication, preventing the formation of the capsid core structure that encapsulates the viral genome and its associated enzymes, reversing transcriptase and integrase
More description
DCC0972 Bi-2051
Novel highly selective, soluble and cellular permeable inhibitor of the P. falciparum protease dipeptidyl aminopeptidase 1 (DPAP1)
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X